Complement associated pathogenic mechanisms in myasthenia gravis

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 904-911

  Tüzün, Erdem ^a,b   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Autoimmunity; Classical pathway; Complement; Experimental autoimmune myasthenia gravis; Myasthenia gravis

Indexed keywords

COBROTOXIN; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 ANTIBODY; COMPLEMENT COMPONENT C6 ANTIBODY; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; REVIEW;

ANIMALS; AUTOANTIBODIES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION;

EID: 84879177463     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.003     Document Type: Review

References (76)

1. Vincent A. Immunology of disorders of neuromuscular transmission. Acta Neurol Scand Suppl 2006, 183:1-7.
2. Christadoss P., Poussin M., Deng C. Animal models of myasthenia gravis. Clin Immunol 2000, 94:75-87.
3. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 2006, 116:2843-2854.
4. Lang B., Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2003, 2:94-100.
5. García-Carrasco M., Escárcega R.O., Fuentes-Alexandro S., Riebeling C., Cervera R. Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 2007, 6:373-378.
6. Berrih-Aknin S., Ragheb S., le Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B cell therapy in myasthenia gravis. Autoimmun Rev 2013, 12:885-893. (this issue).
7. Dalakas M.C. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2012, 11:203-206.
8. Engel A.G., Sahashi K., Fumagalli G. The immunopathology of acquired myasthenia gravis. Ann N Y Acad Sci 1981, 377:158-174.
9. Sahashi K., Engel A.G., Lambert E.H., Howard F.M. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980, 39:160-172.
10. Engel A.G., Lambert E.H., Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977, 52:267-280.
11. Howard F.M., Lennon V.A., Finley J., Matsumoto J., Elveback L.R. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987, 505:526-538.
12. Engel A.G., Fumagalli G. Mechanisms of acetylcholine receptor loss from the neuromuscular junction. Ciba Found Symp 1982, 90:197-224.
13. Tuzun E., Saini S.S., Ghosh S., Rowin J., Meriggioli M.N., Christadoss P. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord 2006, 16:137-143.
14. Tuzun E., Scott B.G., Goluszko E., Higgs S., Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 2003, 171:3847-3854.
15. Nastuk W.L., Plescia O.J., Osserman K.E. Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med 1960, 105:177-184.
16. Casali P., Borzini P., Zanussi C. Immune complexes in myasthenia gravis. Lancet 1976, 2:378.
17. Tsujihata M., Yoshimura T., Satoh A., Kinoshita I., Matsuo H., Mori M., et al. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 1989, 39:1359-1363.
18. Romi F., Kristoffersen E.K., Aarli J.A., Gilhus N.E. The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J Neuroimmunol 2005, 158:191-194.
19. Liu A., Lin H., Liu Y., Cao X., Wang X., Li Z. Correlation of C3 level with severity of generalized myasthenia gravis. Muscle Nerve 2009, 40:801-808.
20. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004, 291:2367-2375.
21. Thorlacius S., Mollnes T.E., Garred P., Aarli J.A., Matre R., Tönder O., et al. Plasma exchange in myasthenia gravis: changes in serum complement and immunoglobulins. Acta Neurol Scand 1988, 78:221-227.
22. Liu Y., Wang W., Li J. Evaluation of serum IgG subclass concentrations in myasthenia gravis patients. Int J Neurosci 2011, 121:570-574.
23. Lennon V.A., Seybold M.E., Lindstrom J.M., Cochrane C., Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978, 147:973-983.
24. Tsujihata M., Satoh A., Yoshimura T., Motomura M., Takeo G., Matsuo H., et al. Effect of myasthenic immunoglobulin G on motor end-plate morphology. J Neurol 2003, 250:75-82.
25. Howard J.F., Sanders D.B. Passive transfer of human myasthenia gravis to rats: 1. Electrophysiology of the developing neuromuscular block. Neurology 1980, 30:760-764.
26. Ashizawa T., Appel S.H. Complement-dependent lysis of cultured rat myotubes by myasthenic immunoglobulins. Neurology 1985, 35:1748-1753.
27. Childs L.A., Harrison R., Lunt G.G. Complement-dependent toxicity of serum from myasthenic patients to muscle cells in culture. J Neuroimmunol 1985, 9:69-80.
28. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
29. Yang H., Wu B., Tüzün E., Saini S.S., Li J., Allman W., et al. A new mouse model of autoimmune ocular myasthenia gravis. Invest Ophthalmol Vis Sci 2007, 48:5101-5111.
30. Wu X., Tuzun E., Li J., Xiao T., Saini S.S., Qi H., et al. Ocular and generalized myasthenia gravis induced by human acetylcholine receptor γ subunit immunization. Muscle Nerve 2012, 45:209-216.
31. Soltys J., Gong B., Kaminski H.J., Zhou Y., Kusner L.L. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?. Ann N Y Acad Sci 2008, 1132:220-224.
32. Kaminski H.J., Li Z., Richmonds C., Lin F., Medof M.E. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol 2004, 189:333-342.
33. Zhou Y., Gong B., Lin F., Rother R.P., Medof M.E., Kaminski H.J. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 2007, 179:8562-8567.
34. Liyanage Y., Hoch W., Beeson D., Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002, 25:4-16.
35. Vincent A., Leite M.I. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005, 18:519-525.
36. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013, 12:931-935. (this issue).
37. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584.
38. Verschuuren J.J.G.M., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez P.M., et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12:918-923. (this issue).
39. Klooster R., Plomp J.J., Huijbers M.G., Niks E.H., Straasheijm K.R., Detmers F.J., et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
40. Mori S., Kubo S., Akiyoshi T., Yamada S., Miyazaki T., Hotta H., et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012, 180:798-810.
41. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005, 57:289-293.
42. Tüzün E., Yilmaz V., Parman Y., Oflazer P., Deymeer F., Saruhan-Direskeneli G. Increased complement consumption in MuSK-antibody-positive myasthenia gravis patients. Med Princ Pract 2011, 20:581-583.
43. Viegas S., Jacobson L., Waters P., Cossins J., Jacob S., Leite M.I., et al. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 2012, 234:506-512.
44. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
45. Christadoss P., Kaul R., Shenoy M., Goluszko E. Establishment of a mouse model of myasthenia gravis which mimics human myasthenia gravis pathogenesis for immune intervention. Adv Exp Med Biol 1995, 383:195-199.
46. Graus Y.M., Verschuuren J.J., Spaans F., Jennekens F., van Breda Vriesman P.J., De Baets M.H. Age-related resistance to experimental autoimmune myasthenia gravis in rats. J Immunol 1993, 150:4093-4103.
47. Engel A.G., Sakakibara H., Sahashi K., Lindstrom J.M., Lambert E.H., Lennon V.A. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor. Neurology 1979, 29:179-188.
48. Christadoss P. C5 gene influences the development of murine myasthenia gravis. J Immunol 1988, 140:2589-2592.
49. Chamberlain-Banoub J., Neal J.W., Mizuno M., Harris C.L., Morgan B.P. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 2006, 146:278-286.
50. Haviland D.L., Haviland J.C., Fleischer D.T., Wetsel R.A. Structure of the murine fifth complement component (C5) gene. A large, highly interrupted gene with a variant donor splice site and organizational homology with the third and fourth complement component genes. J Biol Chem 1991, 266:11818-11825.
51. Morgan E.L., Sanderson S., Scholz W., Noonan D.J., Weigle W.O., Hugli T.E. Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis. J Immunol 1992, 148:3937-3942.
52. O'Barr S., Cooper N.R. The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease. J Neuroimmunol 2000, 109:87-94.
53. Qi H., Tüzün E., Allman W., Saini S.S., Penabad Z.R., Pierangeli S., et al. C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol 2008, 196:101-106.
54. Tsutsumi A., Takahashi R., Sumida T. Mannose binding lectin: genetics and autoimmune disease. Autoimmun Rev 2005, 4:364-372.
55. Li J., Qi H., Tüzün E., Allman W., Yilmaz V., Saini S.S., et al. Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis. J Neuroimmunol 2009, 208:40-45.
56. Ruiz-Argüelles A., Llorente L. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun Rev 2007, 6:155-161.
57. Lin F., Kaminski H.J., Conti-Fine B.M., Wang W., Richmonds C., Medof M.E. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002, 110:1269-1274.
58. Longhi M.P., Sivasankar B., Omidvar N., Morgan B.P., Gallimore A. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. J Immunol 2005, 175:7098-7102.
59. Qin X., Ferris S., Hu W., Guo F., Ziegeler G., Halperin J.A. Analysis of the promoters and 5'-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes. Genes Immun 2006, 7:287-297.
60. Tüzün E., Saini S.S., Morgan B.P., Christadoss P. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J Neuroimmunol 2006, 181:29-33.
61. Kaminski H.J., Kusner L.L., Richmonds C., Medof M.E., Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol 2006, 202:287-293.
62. Soltys J., Halperin J.A., Xuebin Q. DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis. J Neuroimmunol 2012, 244:63-69.
63. Soltys J., Wu X. Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis. J Inflamm (Lond) 2012, 9:20.
64. Biesecker G., Gomez C.M. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 1989, 142:2654-2659.
65. Piddlesden S.J., Jiang S., Levin J.L., Vincent A., Morgan B.P. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996, 71:173-177.
66. Piddlesden S.J., Storch M.K., Hibbs M., Freeman A.M., Lassmann H., Morgan B.P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994, 152:5477-5484.
67. Jung S., Toyka K.V., Hartung H.P. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci Lett 1995, 200:167-170.
68. Goodfellow R.M., Williams A.S., Levin J.L., Williams B.D., Morgan B.P. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin Exp Immunol 2000, 119:210-216.
69. Soltys J., Kusner L.L., Young A., Richmonds C., Hatala D., Gong B., et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009, 65:67-75.
70. Doria A., Canova M., Tonon M., Zen M., Rampudda E., Bassi N., et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 2008, 8:24-28.
71. Roumenina L.T., Sène D., Radanova M., Blouin J., Halbwachs-Mecarelli L., Dragon-Durey M.A., et al. Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. J Immunol 2011, 187:4369-4373.
72. Tüzün E., Li J., Saini S.S., Yang H., Christadoss P. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol 2007, 182:167-176.
73. Kallenberg C.G. Anti-C1q autoantibodies. Autoimmun Rev 2008, 7:612-615.
74. Espinosa G., Berman H., Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011, 10:664-668.
75. Zareba K.M. Eculizumab: a novel therapy for paroxysmal nocturnal hemoglobinuria. Drugs Today (Barc) 2007, 43:539-546.
76. Díaz-Manera J., Rojas García R., Illa I. Treatment strategies for myasthenia gravis: an update. Expert Opin Pharmacother 2012, 13:1873-1883.